Morgan Stanley resumed coverage on Zealand Pharma
$ZEAL
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2024 | Buy | Berenberg | |
| 8/8/2023 | Equal-Weight | Morgan Stanley | |
| 11/16/2022 | Overweight → Equal-Weight | Morgan Stanley | |
| 1/11/2022 | Hold → Buy | Jefferies |
15F-12B - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
S-8 POS - Zealand Pharma A/S (0001674988) (Filer)
Berenberg initiated coverage of Zealand Pharma with a rating of Buy
Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight
Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)
Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspectionThe reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pendingZealand remains committed to working with the FDA and the third-party manufacturer to bring dasiglucagon to patients in the U.S. as soon as possible Copenhagen, Denmark, October 9, 2024 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 200
Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide's groundbreaking results from Phase II study Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis (stages 2 or 3), and LIVERAGE-Cirrhosis in those with MASH and cirrhosis (stage 4) Copenhagen, Denmark, October 8, 2024 –
Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 45/2024 from September 12, 2024, Zealand announced an increase in share capital relating t
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades
COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Henriette Wennicke as Zealand's Chief Financial Officer starting November 1, 2022. Henriette Wennicke comes to Zealand with broad finance and business experience at large organizations, including in healthcare, where she has led financial planning and R&D portfolio management. She is currently the Vice President and Head of Investor Relations and Treasury at GN Store Nord, a global leader in inte
Press Release - No. 2/2022 Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer David Kendall named Zealand Pharma CMOFollows Zealand Pharma's appointment of Adam Steensberg as CEO and decision to refocus strategyKendall has over 35 years of diabetes and metabolic disease experience including nearly two decades in the pharma industry Copenhagen, DK and Boston, MA, U.S. June 2, 2022 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of David M. Kendall, M.D., as Chief Medical Officer. Dr. Kendall most recently
Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. The increase is a consequence of the exercise of warrants granted under two o
Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 13,000 divided into 13,000 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's incentive scheme
Company announcement - No. 39 / 2024 Zealand Pharma Announces Financial Results for the First Half of 2024 Very strong progress across R&D pipeline followed by substantial capital raise enabling further investments to accelerate the development programs for wholly owned obesity assets. Extremely encouraging weight loss and tolerability data announced with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial)Impressive data from Boehringer Ingelheim's Phase 2 clinical trial with survodutide in MASH presented at the EASL congress in Milan, ItalySignificant strengthening of the balance sheet with completion of upsized equity offering raising gross proceeds of DKK 7 bill
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines AgencyCopenhagen, Denmark, May 31, 2024 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending granting marketing authorization for dasiglucagon solution for injection in the treatment of severe hypoglycemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company's amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396 In development as a non-incretin peptide therapy for the potential management of overweight and obesity
Company announcement – No. 43 / 2022 Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WI